Kexing Biopharm signed a Drug Cooperation Agreement with Haichang Biotech to obtain the commercial license of HC007 (a complex preparation for injection, a generic drug of a broad-spectrum anticancer drug) in all regions except the US.
2020
2020
The company was approved to set up the "Shenzhen postdoctoral innovation practice base".
2020
2020
The company successfully landed on the A-share technology innovation board with the stock code of 688136, becoming the leader of high quality biologicals.
2020
2020
Our technology center was ratified as the "Guangdong Gene Engineering Recombinant Protein Therapeutics Engineering Technology Center".
2020
2020
Our technology center was ratified as the "Shandong Protein Therapeutics Engineering Laboratory".
2019
2019
The company was restructured into Kexing Biopharmaceutical Co., Ltd. (Kexing Biopharm).
2019
2019
We launched the slogan "Precise Products, Predictable Effects, Health Protection" and the new logo.
2018
2018
Shandong Kexing Bioproducts Co., Ltd. was established as an industrial platform for recombinant human erythropoietin.
2017
2017
Our technology center was ratified as the "Shandong Provincial Enterprise-level Technology Center"
2014
2014
We integrated the traditional Chinese medicine business focusing on KEHUANG CAPSULE around hepatopathy treatment.
2009
2009
The EPO agent not containing albumin obtained the certificate of invention patent (patent No. ZL200610146206.0).
2002
2002
Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO) was officially approved for production.
2001
2001
"Human Granulocyte Colony-stimulating Factor Injection"(WHITE-C) was officially approved for production.
2000
2000
Shenzhen Sinovac was recognized by the Ministry of Science and Technology as the "Industrialization Base of National 863 Plan Achievement"
1998
1998
"Human Erythropoietin Injection (CHO Cell)" (EPOSINO) was officially approved for production as Class II biological products.
1997
1997
Shandong Kexing Bioproducts Co., Ltd. was established as an industrial platform for recombinant human erythropoietin.
1996
1996
"Human Interferon α1b for Injection" (SINOGEN) was officially approved for production as Class I biological products.
1989
1989
Shenzhen Kexing Bioproducts Co., Ltd., was established as an industrial base for interferon production.